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Targeted therapy directed against rare disease-propagating leukaemic stem cells 
(LSCs) is a promising prospect for improving the outcome of acute myeloid 
leukaemia (AML) patients. Thus, distinguishing LSCs from normal haematopoietic 
stem and progenitor cells (HSPCs) is essential. The CLEC12A receptor has been 
proposed as a specific marker of LSCs, and consequently as an appealing treatment 
target. To explore the role of CLEC12A in further detail, we investigated whether a 
sorting strategy based on the activity of aldehyde dehydrogenase and CLEC12A 
expression could separate residual normal HSPCs from LSCs in bone marrow from 
5 AML patients. We demonstrate that this distinction was possible in 2/5 cases, 
however with evidence of pre-leukaemic mutations in the CLEC12A- stem cells in 
one case. In contrast, cytogenetic and/or molecular aberrations were detected in 
both the CLEC12A+/- cell subsets in 3/5 AML cases studied. Furthermore, targeted 
next generation sequencing (NGS) of the sorted cell subsets revealed a pronounced 
clonal heterogeneity in the CLEC12A- cells suggestive of the leukaemia often 
originating in this immature cell subset. In conclusion, we provide proof-of-concept 
that precision diagnostics employing targeted cytogenetic/NGS-based analyses on 
highly purified cell subsets could be a powerful tool for selecting patients eligible for 
LSC-directed therapy.  
 
 
 
Leukaemic stem cells, acute myeloid leukaemia, hMICL, ALDH, precision medicine 
 
 
 
There is an unmet need to improve the outcome of acute myeloid leukaemia (AML) 
patients, and novel targeted treatment strategies directed against e.g. cell surface 
proteins, recurrent mutations and signalling pathways, are rapidly being developed 
and tested in clinical trials (Wei & Tiong, 2017). However, given the extreme 
biological heterogeneity seen in AML, a prerequisite for such treatments to become 
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successful will, to a large extent, depend on the selection of the right patients for the 
relevant combination of targeted therapy.  
 
In AML, the neoplastic cells are believed to be hierarchically organised, with rare 
disease-propagating leukaemic stem cells (LSCs) residing at the apex, and evidence 
of the existence and clinical relevance of such LSCs has been subject to an 
extensive amount of research over the past two decades (Bonnet, 2005; 
Yanagisawa et al, 2016; Thomas & Majeti, 2017). Current literature suggests these 
particular cells to possess stem cell properties in terms of quiescence, self-renewal 
capacity and an increased resistance to chemotherapy (Griessinger et al, 2014), and 
LSCs are thought to be responsible for relapse in the vast majority of AML patients 
(Bonnet, 2005). It is noteworthy that, while the identification of recurrently mutated 
genes in AML has expanded our view of AML pathophysiology (Cancer Genome 
Atlas Research Network et al, 2013), studies integrating knowledge of the mutational 
architecture with the hierarchical cancer stem cell model are sparse (Chesnais et al, 
2017; Klco et al, 2014). Thus, LSCs are attractive targets in the development of new 
treatment modalities in AML (Bruserud et al, 2017), and a precise and in-depth 
characterization of these cells, including an understanding of how they differ from 
their normal counterparts, is essential. 
 
In this regard, the C-type lectin domain family 12, member A (CLEC12A) receptor, a 
relevant marker of leukaemic blasts (Larsen et al, 2012; Roug et al, 2014), has been 
proposed as a specific marker of LSCs in AML (van Rhenen et al, 2007a; Terwijn et 
al, 2014), as the CLEC12A protein is not expressed on normal CD34+CD38- cells, 
but aberrant expression on this subset of cells has been demonstrated in AML (van 
Rhenen et al, 2007a; 2007b). In addition, we have recently shown the relevance of 
the marker in myelodysplastic syndrome (MDS) and pointed out important 
differences in the applicability of the marker in these biologically different disease 
entities (Toft-Petersen et al, 2016). Given this, the CLEC12A receptor is an attractive 
treatment target in AML, and current developments in this regard include both 
CLEC12A-CD3 bispecific antibodies (Leong et al, 2017; Lu et al, 2014) and chimeric 
antigen receptor (CAR)-engineered T-cells (CAR-T-cells) directed against CLEC12A 
(Laborda et al, 2017; Tashiro et al, 2017; Wang et al, 2018) and, most recently, the 
development of a novel antibody-drug conjugate (Jiang et al, 2018).  
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High activity of the cytosolic enzyme aldehyde dehydrogenase (ALDH) has been 
associated with normal haematopoietic stem and progenitor cells (HSPCs) (Storms 
et al, 1999; Pearce et al, 2005; Hess et al, 2004; Gentry et al, 2007) as well as 
cancer stem cells (CSCs) in both solid tumours (Ajani et al, 2015) and 
haematological malignancies (Hoang et al, 2013; Gerber et al, 2012; 2011; Wu et al, 
2013). Moreover, a high level of ALDH activity has been proposed as a tool for 
separating LSCs from normal HSPCs (Hoang et al, 2015; Schuurhuis et al, 2013). 
Specifically, most cases of AML have a very small fraction of cells with high levels of 
ALDH activity; these are termed ALDH bright cells (ALDHbr), and  have been shown 
to represent residual normal HSPCs, while the leukaemic blasts and LSCs display a 
lower ALDH activity (Gerber et al, 2012; Schuurhuis et al, 2013). However, , a larger 
fraction of ALDHbr
 
 cells is evident in up to 20% of AML samples; in these cases, the 
separation of LSCs and non-malignant HSPCs has not been possible (Hoang et al, 
2015).  
While early studies of LSCs focused on the immature CD34+CD38- population 
(Lapidot et al, 1994; Bonnet & Dick, 1997), cells with functional LSC properties can 
also reside in the CD34+CD38+ cell subset (Taussig et al, 2008; Sarry et al, 2011; 
Goardon et al, 2011) and even in the CD34- compartment (Quek et al, 2016; Taussig 
et al, 2010). Moreover, gating of the CD38- stem cell compartment can be 
challenging, especially in diagnostic AML samples where the blast population often 
presents as a continuum of CD34+CD38+/- cells.  
 
In this study, based on the above mentioned current knowledge of LSC 
immunophenotypes and previous studies proposing CLEC12A to be a highly specific 
marker of LSCs in AML (van Rhenen et al, 2007a; 2007b; Terwijn et al, 2014), we 
employed ALDH activity as a marker of immaturity and investigated whether a 
sorting strategy based on ALDH activity and (the lack of) CLEC12A expression 
without pre-selecting the CD34+CD38- cells could identify residual normal HSPCs in 
bone marrow (BM) from five AML patients. Specifically, we hypothesised that cells 
with the ALDHbrCD34+CLEC12A- immunophenotype represent residual normal 
HSPCs and cells with the ALDHbrCLEC12A+ (CD34+/-) immunophenotype to 
represent AML LSCs. We evaluated the purified cell populations in a long-term 
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colony-initiating cell assay (LTC-IC) and by performing cytogenetic, molecular and 
targeted next generation sequencing (NGS) analyses on both the sorted cell subsets 
and the LTC-IC derived colonies. Our data revealed a hitherto unrealised 
heterogeneity in the applicability of CLEC12A as an LSC marker in AML and strongly 
indicate the need for thorough and precise diagnostics on biologically relevant cell 
subsets in order to better select patients suitable for CLEC12A targeted therapy. 
 
M  
 
Patient samples 
Cryopreserved BM samples from five AML patients and one chronic myeloid 
leukaemia (CML) patient with myeloid blast crisis (served as a positive control) were 
obtained as excess material taken as part of the diagnostic process at the 
Department of Haematology, Aarhus University Hospital. The AML patients were 
selected to represent various subtypes of AML and, in addition, the selection was 
based on the presence of known cytogenetic and/or molecular aberrancies obtained 
by routine karyotyping and screening for mutations in NPM1, FLT3-internal tandem 
duplication (ITD), FLT3 D835, WT1 exon 7, KIT and CEBPA. Normal BM samples 
(NBM, n=2) from healthy volunteers served as controls and were obtained in the 
setting of BM harvest for allogeneic BM transplantation. The study was conducted in 
accordance with the Declaration of Helsinki and was approved by the local ethics 
committee. Mononuclear cells (MNCs) were obtained by Lymphoprep (Axis-Shield 
plc., Dundee, Scotland) separation according to the manufacturer’s instructions, 
cryopreserved in 10% dimethylsulfoxide, and stored in liquid nitrogen. Patient 
characteristics are given in Table I. 
 
The Aldefluor™ Assay and surface staining 
Cryopreserved MNCs were thawed in a 37°C water bath and resuspended in 
RoboSep Buffer (StemCell Technologies, Vancouver, BC, Canada) with 15% heat-
inactivated fetal calf serum (Biochrom, GmbH, Berlin, Germany). Next, cells were 
stained with 2.5 μl pre-titrated AldefluorTM reagent in AldefluorTM Buffer (StemCell 
Technologies) and incubated at 37°C for 45 min. Subsequently, cells were washed 
and resuspended in cold AldefluorTM Buffer, kept on ice, and stained for 45 min with 
the monoclonal antibodies listed in Table SI.  
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Fluorescence activated cell sorting 
Fluorescence activated cell sorting was performed on a BD FACSAriaTM III (BD 
Biosciences, San Jose, CA, USA). Compensation was set using unstained and 
AldefluorTM single stained cells combined with UltraComp eBeads (eBioscience, San 
Diego, CA, USA) together with the relevant fluorochrome conjugated antibodies. In 
the gating strategy used (Fig 1 and S1), live cells were identified in a forward scatter 
(FSC)/side scatter (SSC) plot after which doublet exclusion was done on both FSC 
and SSC height vs. area plots. As monocytes display a relatively high level of ALDH 
activity (Storms et al, 1999), we selected CD14 negative cells and defined the 
ALDHbr cell subset (Aldefluor bright and SSC low) on this cell population. The lower 
limit of the ALDHbr cells was set, taking the contour of the ALDHlow cells into account. 
Next, in the ALDHbr cells, the ALDHbrCLEC12A+ and ALDHbrCD34+CLEC12A- gates 
were defined. The CLEC12A+/- gates were set by use of internal negative controls 
(lymphocytes), and CLEC12A+ cells were not separated further based on 
fluorescence intensity. For cultures, two cell subsets were sorted, namely 
ALDHbrCLEC12A+ and ALDHbrCD34+CLEC12A-. The equivalent subsets from two 
NBM samples were sorted as controls. For patients with a cytogenetic aberration, 
additional cells from each subset were sorted directly onto poly-L-lysine coated 
slides (Thermo Fischer Scientific Inc., Waltham, MA, USA), and for patients with a 
given molecular aberration, cells from each subset were sorted into phosphate-
buffered saline (PBS) (Thermo Fischer Scientific Inc) and stored at -80°C for later 
molecular genetic analyses. Due to the rarity of the cell populations, the purity of the 
sorted subsets was determined in 9 out of 18 total subsets (Table SII). For the 
ALDHbrCLEC12A+ subset, purity was on average 90.3% (n=5). For the 
ALDHbr
 
CD34+CLEC12A- subset, purity averaged 96.5% (n=4). Data was analysed 
using FlowJo Data Analysis Software, version X (BD Biosciences). 
Long-term colony initiating cell assay 
The LTC-IC assay was performed as described previously (Toft-Petersen et al, 
2016). In brief, sorted subsets were seeded in 96-well collagen-coated plates and 
cultured on irradiated M2-10B4 stromal feeder cells (ATCC, Manassas, Virginia, 
USA) with weekly half-change of medium. After 6 weeks of co-culture, cells were 
harvested and transferred to MethoCult H4435 (StemCell Technologies) for an 
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additional 2 weeks. Colony-forming cells (CFCs) were counted and scored for 
erythroid and myeloid morphology, respectively. Individual CFCs from each subset of 
the originally seeded cells were picked and either cyto-spinned onto poly-L-lysine 
coated slides (Thermo Fischer Scientific Inc.) for subsequent fluorescence in situ 
hybridization (FISH) analyses or resuspended in PBS and stored at -80°C for 
molecular genetic analyses. 
 
Interphase FISH  
Fluorescence in situ hybridization (FISH) analyses were performed as previously 
described (Toft-Petersen et al, 2016). The following locus-specific directly 
fluorescent-labelled probe sets were used according to the manufacturer’s 
instructions: t(8;21)(q22;q22)/RUNX1-RUNX1T1 dual fusion, 11q23/ KMT2A (MLL) 
break apart, 18q21/BCL2 break apart, 7q11.23(ELN)/7q31(D7S486,D7S522), 
t(9;22)(q34;q11)/BCR-ABL1 dual fusion (all from Abbott Molecular, Des Plaines, 
Illinois, USA). To estimate the number of FISH-positive cells on cyto-spun slides of 
individually picked colonies and on cells sorted directly onto slides, a median of 100 
interphase nuclei was evaluated (range 5-101) by two independent observers.  
 
Molecular analyses  
Genomic DNA was extracted from diagnostic BM MNCs using the Maxwell® 16 
Blood DNA Purification Kit on the Maxwell® 16 Instrument (Promega, Madison, WI, 
USA) or, for sorted cell subsets, by use of the QIAamp DNA Blood Mini Kit (Qiagen, 
Hilden, Germany), both according to the manufacturer’s instructions. For individually 
picked colonies and when ≤ 1031 cells were available from the sorted subsets, 
whole genome amplification (WGA) was performed prior to downstream molecular 
analysis using the REPLI-g Single Cell Kit (Qiagen) according to the manufacturer’s 
instructions. Mutations in NPM1, FLT3, ASXL1, TET2, WT1, IDH1 and ZRSR2 were 
investigated by polymerase chain reaction (PCR) with subsequent fragment length 
analyses (NPM1, FLT3, ASXL1, TET2, WT1) or Sanger sequencing (IDH1, ZRSR2). 
Polymerase chain reaction was run on a C1000 Touch™ Thermal Cycler (Bio-Rad, 
Hercules, CA, USA) for 15 min at 95°C followed by 35 cycles of 30 s at 95°C, 1 min 
at 58°C, and 1 min at 72°C followed by an elongation step for 60 min at 60°C (for 
fragment length analysis) or 10 min at 72°C (for Sanger sequencing). Sanger 
sequencing was performed using the BigDye Terminator v1.1 Cycle Sequencing Kit 
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(Thermo Fischer Scientific Inc.). Fragment length analysis and Sanger sequencing 
were run on a 3500 Genetic Analyzer (Thermo Fischer Scientific Inc.). All primer 
sequences are listed in Table SIII.  
 
Targeted next generation sequencing 
Targeted next generation sequencing (NGS) was performed with the Myeloid 
Tumour Solution 30 gene panel (SOPHiA Genetics, Saint Sulpice, Switzerland) 
performed according to manufacturer’s instructions and analysed in the SOPHiA 
DDM® analysis software (SOPHiA Genetics). As the WGA reaction can introduce 
errors (Gawad et al, 2016), the quality of the NGS results obtained from samples that 
underwent WGA was assessed by calculating the standard deviation (SD) of variant 
allele frequencies (VAFs) of heterozygous single nucleotide polymorphisms (SNPs) 
(depth > 2500 reads and 10% < VAF < 90%) in the sequenced regions of the 30 
investigated genes identified in the unfractionated BM sample (not exposed to WGA 
prior to targeted NGS) and the sorted samples (exposed to WGA) (Fig S2, Table 
SIV). Reference sequences for mutations identified are given in Table SV. 
 
 
Immunophenotypic characteristics 
For the AML patients, CLEC12A was expressed on 59 – 89% of the leukaemic blasts 
with the highest level of expression on the two CD34- AML cases (AML 4 and 5) 
(Table I). While the CD34+CD38- cell subsets were devoid of CLEC12A expression 
in the CD34- cases, the opposite was the case in the CD34+ cases of AML (Table I). 
The immunophenotypic characteristics of the six patient samples with respect to 
ALDH activity, CD34 and CLEC12A expression are depicted in Fig 1. Of note, the 
percentage of ALDHbr cells varied between AML samples (range 0.1 - 5.0% of 
CD14- cells). Thus, AML 1, 4 and 5 displayed low percentages of ALDHbr cells 
(range 0.1 – 0.9% of CD14- cells), while AML 2 and 3 displayed larger fractions of 
ALDHbr cells (range 3.4 – 5.0% of CD14- cells). This finding is in concordance with 
previous studies of ALDH activity in AML (Hoang et al, 2015; Cheung et al, 2007). In 
line with previous findings (Gerber et al, 2011), the CML blast crisis patient (CML 1) 
had a very large percentage of ALDHbr cells (41.1% of CD14- cells). By back-gating 
of the ALDHbrCD34+CLEC12A- cell subset into a CD34 vs. CD38 plot for all samples 
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including NBM, we verified that these cells had the immunophenotypic profile of early 
HSPCs with dim to no expression of CD38 (Fig 1, last column and Fig S1). 
 
In AML, cells with LTC-IC activity are present in the ALDHbr
In order to evaluate the stem cell properties of the ALDH
CD34+CLEC12A- cell 
subset 
brCLEC12A+ and 
ALDHbrCD34+CLEC12A- cell populations in AML, we studied the highly purified cell 
subsets in the LTC-IC assay. As CML is known to originate in the haematopoietic 
stem cell compartment (Barnes & Melo, 2006), and BM from CML patients is known 
to have high levels of ALDH activity (Gerber et al, 2011), we also sorted 
ALDHbrCD34+CLEC12A- and ALDHbr
 
CLEC12A+ BM cells from a CML blast crisis 
patient as a positive control. Furthermore, equivalent cell subsets from NBM cultured 
simultaneously served as a quality control of the assay itself. 
In the case of NBM, no CFCs were evident after 8 weeks of culture in the LTC-IC 
assay when ALDHbrCLEC12A+ cells were originally seeded (Fig 2). This suggests 
that normal ALDHbrCLEC12A+ cells do not possess functional stem cell properties 
and most probably represent normal short-lived committed myeloid progenitors (Bill 
et al, 2018). For the AML samples, the ALDHbrCLEC12A+ cells did not produce 
CFCs in the LTC-IC assay with the exception of AML 1 that gave rise to CFCs that 
were negative for t(8;21) when evaluated by FISH (Fig 2, Table II). This growth of 
aberration-negative CFCs from ALDHbrCLEC12A+ cells in AML 1 was unexpected, 
and we cannot formally exclude that the growth of CFCs in this case could be due to 
impurities of the sorting procedure. Unfortunately, we were not able to assess the 
purity of the sorted subset in this particular case due to very limited material, but, in 
general, the average sorting purity of the ALDHbrCLEC12A+ cell subset was lower 
for the ALDHbrCD34+CLEC12A- cell subset (Table SII). In contrast to NBM and 
AML, the ALDHbr
 
CLEC12A+ cells from CML 1 produced a large number of CFCs 
(Fig 2), which were BCR-ABL1+ (Table II), indicating the self-renewal potential, and 
thereby the LSC properties, of these cells.  
When evaluating the ALDHbrCD34+CLEC12A- cell population in the LTC-IC assay, 
CFCs were produced in both NBM and in all cases of AML (Fig 2). However, when 
the individually picked CFCs from the 5 AML cases were investigated with 
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subsequent FISH or molecular analyses these were always negative for the known 
cytogenetic or molecular aberrancy (Table II). In the case of CML 1, the number of 
CFCs produced was so high that the discs were uncountable (Fig 2), and all 
harboured the BCR-ABL1 aberration (Table II).  
 
The data from the LTC-IC assay thus suggested that residual normal haematopoietic 
stem cells with self-renewal capacity were present among the 
ALDHbr
 
CD34+CLEC12A- cells in AML BM. However, as the leukaemic AML cells 
failed to produce CFCs in the LTC-IC setup, we did not obtain functional evidence of 
their possible LSC nature in either of the two CLEC12A+/- cell subsets. This lack of 
leukaemic growth in the LTC-IC assay is in line with previous reports (Hoang et al, 
2015).  
In AML, the ALDHbr
Given the fact that the growth of AML stem cells is not always supported in the LTC-
IC assay or even in xenograft models (van Gosliga et al, 2007; Ailles et al, 1999), we 
next investigated whether the findings from the LTC-IC assay were due to a biased 
selection of normal HSPCs in the culturing assay. Thus, the sorted uncultured cells 
from the ALDH
CD34+CLEC12A- cell subset is heterogeneous 
brCLEC12A+ and ALDHbrCD34+CLEC12A- subpopulations were 
analysed by FISH or molecular methods (Table II). Interestingly, in the case of AML 
1 and 5, we were able to confirm the findings from the LTC-IC results, as the sorted 
ALDHbrCD34+CLEC12A- cells were devoid of the known aberrations characterising 
the neoplastic cells, while the ALDHbrCLEC12A+ cells turned out to be either positive 
or partially positive. In contrast, in AML 2, 3 and 4, both the sorted 
ALDHbrCD34+CLEC12A- cells and the ALDHbrCLEC12A+ cells were positive for the 
known malignant aberrancy (Table II). However, in AML 3 and 4, the approximate 
percentages of mutated alleles were lower in the ALDHbrCD34+CLEC12A- cell 
subset than in the ALDHbrCLEC12A+ cell subset (Table II). Interestingly, irrespective 
of whether the ALDHbrCD34+CLEC12A- were finally found harbour malignant cells 
or not, this seemed to be independent of whether the AML blasts and/or the 
CD34+CD38- cells were CLEC12A positive (Table I). As expected, in the CML 
patient, both the sorted ALDHbrCD34+CLEC12A- and the ALDHbr
 
CLEC12A+ cells 
were BCR-ABL1+. 
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Collectively, the analyses of the sorted cell populations for the a priori known 
aberrancies indicate that ALDH activity and the lack of CLEC12A expression can be 
useful in defining residual normal HSPCs in selected cases of AML. However, in 
other cases, this approach is not feasible. 
 
Targeted NGS indicates a hierarchical relationship between the 
ALDHbrCD34+CLEC12A- and ALDHbr
Given that, on average, AML patients harbour ~5 recurrent mutations (Cancer 
Genome Atlas Research Network et al, 2013), we next sought to perform a more 
exhaustive analysis of the two sorted subsets by performing targeted NGS of 30 
genes known to be recurrently mutated in myeloid malignancies. In the case of AML 
3, 4 and 5, material was available from the diagnostic BM sample together with the 
sorted ALDH
CLEC12A+ subsets and shows that LTC-IC 
derived CFCs harbour pre-leukaemic mutations  
brCD34+CLEC12A- and ALDHbrCLEC12A+ cell subsets; NGS revealed 
additional mutations in all three cases (Table III). Thus, in addition to the FLT3-ITD 
and NPM1 mutations in AML 4, a WT1 mutation, known to be an AML driver 
mutation (Lindsley et al, 2015), was identified. In AML 3 and 5, mutations often 
associated with pre-leukaemia and/or antecedent MDS were detected in addition to 
other recurrent AML driver mutations (Lindsley et al, 2015). While this finding was 
expected in the case of AML 5, who clinically presented with secondary AML 
(sAML), AML 3 presented clinically as a de novo AML (Table I). Overall, the 
mutations detected in the diagnostic BM sample could also be found in the sorted 
subsets, apart from the NPM1 mutation in AML 5, which, as expected, was 
undetectable in the ALDHbrCD34+CLEC12A- cell subset. Interestingly, in all three 
cases, the VAF of mutations in the ALDHbrCLEC12A+ cell subsets were between 45-
49% indicating that the vast majority of these cells harbour the heterozygous 
mutations, except for AML 5, where the NPM1 mutation had a VAF of 26% in the 
ALDHbrCLEC12A+ cell subset. This was in line with the findings by fragment length 
analysis (Table II) and indicative of the ALDHbrCLEC12A+ cells being only partially 
NPM1-mutated. In contrast, the VAFs of the different mutations in the 
ALDHbr
 
CD34+CLEC12A- varied (Table III).  
The finding of pre-leukaemic mutations in AML 3, 4 and 5 prompted us to investigate 
whether the LTC-IC derived colonies could be positive for these aberrations as well. 
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Indeed, 5/13 colonies were ASXL1-mutated in AML 3 and in AML 5, all of the LTC-IC 
derived CFCs (6/6) were TET2 c.1767delT, TET2 c.1932delA and ZRSR2 mutation 
positive. In line with the notion of WT1 mutations being late events in 
leukaemogenesis (Krauth et al, 2015), the CFCs of AML 4 were negative for this 
mutation. Of note, despite a VAF of ~44% for the ASXL1 mutation in AML 3, not all 
colonies derived from the ALDHbr
 
CD34+CLEC12A- subset were pre-leukaemic in 
nature, indicating the co-existence of residual normal HSPCs with pre-leukaemic and 
possibly LSCs in the BM. 
Furthermore, targeted NGS on the sorted ALDHbrCD34+CLEC12A- and 
ALDHbrCLEC12A+ cell subsets revealed marked differences between the two cell 
subsets. While the ALDHbrCLEC12A+ cells predominantly resembled the diagnostic 
BM sample, the ALDHbr
 
CD34+CLEC12A- cells showed a much greater variation in 
VAFs of the detected mutations. As exemplified in AML 3, this variation in VAFs may 
uncover the clonal heterogeneity and hierarchical leukaemic evolution of the different 
subclones (Fig 3). In addition, the finding of pre-leukaemic mutations in some of the 
LTC-IC derived colonies supports previous reports of pronounced functional 
heterogeneity of genetically different subclones (Chesnais et al, 2017; Klco et al, 
2014).  
 
In the upcoming era of precision medicine, it is of great importance to know the 
characteristics of the target cells, yet knowing the details of cell subsets not 
expressing the target is of equal importance. Firstly, it is necessary to understand 
which normal cells are spared by such treatment, and not least to determine whether 
all of the relevant neoplastic cells are indeed targeted as intended. As such, our 
results should be seen in the context of the increasing need for improved treatment 
modalities in AML. The CLEC12A receptor holds great promise as a future treatment 
target and the first clinical trial with a CD3-CLEC12A bispecific antibody in AML has 
been initiated in Europe (EudraCT number 2015-003704-23). In the present study 
we therefore explored CLEC12A in further detail in the setting of AML by 
investigating whether a sorting strategy based on ALDH activity and CLEC12A 
expression could be useful in distinguishing LSCs from residual normal HSPCs. We 
demonstrate that this distinction is, indeed, possible in some AML cases, supporting 
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the current paradigm of CLEC12A as a robust marker of LSCs. However, in 3/5 AML 
cases, the ALDHbr
 
CD34+CLEC12A- cells also harboured the cytogenetic and/or 
molecular aberrations characterising the malignant cells, and in such cases 
CLEC12A targeted treatment would probably not be sufficient to eradicate the 
neoplasm.  
Our data should be seen in continuation of a previous study that combined ALDH 
activity with aberrantly expressed LSC markers, including CLEC12A (Schuurhuis et 
al, 2013). While these authors showed that residual normal HSPCs were ALDHbr and 
LSC-marker negative, their experimentation was devoted to patients with known 
FLT3-ITD or NPM1 mutation (Schuurhuis et al, 2013). Similarly, the earliest studies 
of CLEC12A as a marker of LSCs were also conducted on AML samples with 
primarily FLT3-ITD or NPM1 mutations (van Rhenen et al, 2007a; 2007b; Moshaver 
et al, 2008). These aberrations are, in most cases, known to be late events in 
leukaemogenesis, often occurring in committed myeloid progenitors (Shlush et al, 
2014; Corces-Zimmerman et al, 2014). We have recently demonstrated CLEC12A 
expression on both common myeloid- and granulocyte-macrophage progenitors (Bill 
et al, 2018), and thus in the case of AML 5 (NPM1+, monosomy 7) our data could 
indicate that the leukaemic transformation happened in a CLEC12A+ progenitor cell, 
which would confirm previous findings of Schuurhuis et al (2013). This patient had a 
history of MDS with monosomy 7 and later developed NPM1+ sAML. Even though 
low risk MDS has been shown to propagate from the haematopoietic stem cell 
(Tehranchi et al, 2010; Woll et al, 2014), evidence suggests some high-risk MDS 
subtypes, e.g. monosomy 7 do in fact derive from a later progenitor stage (Dimitriou 
et al, 2016). Thus, despite evidence of pre-leukaemic mutations in the 
ALDHbrCD34+CLEC12A- cell subset, CLEC12A targeted therapy could, 
theoretically, have been beneficial in this patient with sAML. This notion is supported 
by a very recent study by Jongen-Lavrencic et al (2018), showing that, for AML in 
complete remission, detection of persistent mutations in ASXL1, DNM3TA and TET2 
was not correlated with an increased relapse rate. On the other hand, in the case of 
AML 4, the leukaemic mutations (FLT3-ITD+, NPM1+ and WT1+) must have arisen 
in a CLEC12A- cell, as the ALDHbrCD34+CLEC12A- cell subset also harboured 
these mutations, albeit in lower VAFs. Hence, CLEC12A-directed therapy would 
A
u
th
o
r 
M
a
n
u
s
c
ri
p
t
This article is protected by copyright. All rights reserved 
most likely be insufficient to eradicate the most immature AML cells in this particular 
patient.  
 
Another study investigating primarily core-binding factor leukaemias has included 
ALDH activity as a marker of stem cells and found cells with the 
ALDHbrCD34+CD38- immunophenotype to be of non-neoplastic nature (Gerber et al, 
2012). In line with this, the ALDHbrCD34+CLEC12A- cells from AML 1 (t(8;21)) were 
cytogenetically normal when evaluated by FISH. The majority, but not all of the 
ALDHbrCLEC12A+ cells was also negative for t(8;21) (4/100, Table II), indicating that 
adding CLEC12A to the sorting scheme actually refined the separation of normal 
HSPCs from cells with the malignant t(8;21) signature within the ALDHbr cell 
compartment. This contrasts to AML 2, where the sorted ALDHbr
 
CD34+CLEC12A- 
cells were predominantly cytogenetically abnormal (Table II). This patient had a 
complex karyotype but no history of antecedent MDS. It is worth noticing that both 
AML 1 and 2 presented with a large fraction of CD34+CD38-CLEC12A+ cells (Table 
I), which, by current definitions, would indicate CLEC12A as a bona fide LCS marker 
in both cases. However, if one were to choose to target CLEC12A, the predicted 
outcome would be quite different for AML 1 and AML 2. 
While it is known that in a significant proportion of human AML cases, the leukaemic 
cells do not express CD34, there is no consensus on the definition of CD34- AML 
(Kanda et al, 2000). In a recent work, Zeijlemaker et al (2015) suggested that the 
distinction between CD34+ and CD34- AML should be based on the presence / 
absence of aberrant marker expression on the CD34+CD38- cells rather than an 
arbitrary cut-off value for CD34 expression. Previous reports have shown the small 
fraction of CD34+ cells in CD34- AML to often represent residual normal HSPCs 
(Taussig et al, 2010). However, the existence of CD34+ LCSs in CD34- AML has 
recently been demonstrated (Quek et al, 2016), and as such the need for a deeper 
understanding of this subtype of AML remains important. We have previously 
demonstrated that in CD34- AML, the percentage of blasts expressing CLEC12A is 
consistently high (Larsen et al, 2012). In this study, we have evaluated two cases of 
CD34- AML (AML 4 and 5; < 1% CD34+ cells). In the case of AML 4, > 80% of the 
leukaemic CD34- blasts expressed CLEC12A, and it could be tempting to pinpoint 
such a patient for CLEC12A targeted therapy – which in this case would most 
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probably fail, as the ALDHbr
 
CD34+CLEC12A- cells also harboured FLT3-ITD, NPM1 
and WT1 mutations. As mentioned above, CLEC12A might have been a beneficial 
target in the other case of CD34- AML (AML 5), and future research is needed to 
evaluate if CLEC12A could be advantageous as a target in most cases of CD34- and 
other more “mature” cases of AML, equivalent to what is often seen in CD33-directed 
therapy (Walter et al, 2012). 
Our study did not provide functional evidence of LSCs with recognised AML driver 
mutations (e.g. FLT3-ITD or NPM1) in the LTC-IC assay. However, we confirmed the 
findings of previous studies, showing a preponderance of LTC-IC activity in cells with 
early leukaemogenic events, e.g. in epigenetic or chromatin modifying genes, such 
as TET2 and ASXL1 (Chesnais et al, 2017). In addition, the data from targeted NGS 
on highly purified cell subsets strongly suggested a hierarchical relationship between 
the ALDHbrCD34+CLEC12A- and ALDHbrCLEC12A+ cell subsets, indicating that the 
pre-leukaemic and/or founding clones often arise in the most immature 
ALDHbrCD34+CLEC12A- cells with additional driver mutations emerging either in a 
ALDHbrCD34+CLEC12A- cell or in a more mature ALDHbrCLEC12A+ cell. This is 
most evident in the case of AML 3, where the ALDHbrCLEC12A+ cell harboured all 7 
identified mutations in VAFs of 45-49%, indicating that the vast majority of these 
cells harboured all of the mutations, while although all 7 mutations were present in 
the ALDHbrCD34+CLEC12A- cells, the VAFs varied, indicating a linear acquisition of 
mutations (Fig 3). In further support of the accumulative nature of the leukaemic 
events, the LTC-IC derived CFCs were negative for the IDH1 mutation, while 38% of 
the evaluated colonies were ASXL1+. Furthermore, although AML 3 clinically 
presented as de novo AML, the presence of ASXL1 and EZH2 mutations is highly 
indicative of a subclinical antecedent MDS phase (Lindsley et al, 2015), and the 
finding of neoplastic CLEC12A- cells would be in accordance with our previous study 
of CLEC12A in MDS (Toft-Petersen et al, 2016). Similarly, in the case of AML 5, the 
colonies from LTC-IC harboured founding mutations in TET2 c.1767delT, TET2 
c.1932delA and ZRSR2, while being devoid of the NPM1 mutation. Taken together, 
targeted NGS analyses on rigorously purified cell subsets, in contrast to bulk BM 
analysis, can reveal knowledge of the clonal evolution in a given patient sample and 
thus help determine – if not the LSC, as this by strict definitions requires functional 
studies – then the most immature cell subset to harbour a given set of mutations. 
A
u
th
o
r 
M
a
n
u
s
c
ri
p
t
This article is protected by copyright. All rights reserved 
Naturally, as our results are based on the evaluation of very few cells, the lack of a 
specific mutation in a given cell subset should, of course, be interpreted with caution. 
Nevertheless, we feel that the presented method, if standardized and optimized to 
the clinical setting, could be very useful. For example, in the setting of a clinical trial 
testing a given targeted treatment, this technique could prove valuable in the 
evaluation of the efficacy of such therapies based on information of the clonal 
architecture in different AML stem cell compartments. Ultimately, assuming that LSC 
marker positivity/negativity in immature AML cells and mutational status in the 
respective cell compartments is correlated with treatment response, a similar 
methodology could indeed serve as a prerequisite for successful identification of the 
particular patients likely to benefit from a given treatment directed against any cell 
surface molecule.  
 
In conclusion, our study adds to the understanding of CLEC12A in AML and cautions 
that a detailed determination of the leukaemic cell of origin “up front” will be 
necessary to predict treatment response and direct the right patients for CLEC12A 
targeted therapy. Thus, we predict a future need for a refinement of the initial 
diagnostics where cytogenetic and molecular analyses ideally should be performed 
on sorted cell subsets based on relevant markers and/or treatment targets. Such an 
approach indeed appears to be essential in order to practice personalised medicine 
in a complex disease such as AML. 
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De novo 32 ~ 50% CD34 high 78% 54% 
46,XX,t(6;10)(q22;q25)c[14] / 
46,idem,t(8;21)(q22;q22)[11] 
- 
De novo 79 > 80% CD34 + / - 59% 21% 
43,XX,-3,der(3;11)(q10;q10), 
-11,-14,-18,+mar[25] 
- 
De novo 75 70-80% CD34 + / - 69% 6%  46,XY[25] IDH1 R132C  
De novo 86 > 90% CD34 - * 81% 0.7% (2 events) 46,XY[25] 
NPM1 mut A  
FLT3-ITD 
sAML (MDS) 80 > 95% CD34 - * 89% 2.7% (2 events) 45,XY,-7[22/25] NPM1 mut A 
CML-BC 67 ~ 40% CD34 + 53% 13% ND BCR-ABL1 
* less than 1% CD34+ cells 
AML: acute myeloid leukaemia; BM: bone marrow; CML-BC: chronic myeloid leukaemia in blast crisis; ITD: internal tandem duplication; MDS: 
myelodysplastic syndrome.ND: not done; NK: normal karyotype; sAML: secondary acute myeloid leukaemia. 
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-  
 
 
 
 - 
Sorted cells 
 
LTC-IC 
aberration-positive 
colonies (n)/ 
total colonies 
evaluated (N) 
Sorted cells 
 
LTC-IC 
aberration-positive 
colonies (n)/ 
total colonies 
evaluated (N) 
AML 1  RUNX1-RUNX1T1# 4/100 (4%) 0/8 (0%) 0/44 (0%) 0/7 (0%) 
AML 2  
11q23/KMT2A 94/100 (94%)  # 
No colonies  
in LTC-IC 
85/100 (85%)  0/6 (0%)  
18q21/BCL2 90/100 (90%) # 
No colonies  
in LTC-IC 
91/100 (91%) 0/6 (0%) 
AML 3  IDH1 mutation$ 
IDH1 mutation+ 
(20.000 sorted cells) 
~ 45% 
No colonies  
in LTC-IC 
IDH1 mutation+ 
(833 sorted cells) 
~ 30%  
0/16 (0%) 
AML 4  
NPM1 mutation A
NPM1 mutation A+ 
§
 (9722 sorted cells) 
~ 45% 
No colonies  
in LTC-IC 
NPM1 mutation+ 
(1031 sorted cells) 
~ 25% 
0/16 (0%) 
FLT3-ITD§
FLT3-ITD+ 
  (9722 sorted cells) 
~ 50% 
No colonies  
in LTC-IC 
FLT3-ITD+ 
 (1031 sorted cells) 
~ 15% 
0/16 (0%) 
AML 5  
7q31.23/ELN# 90/90 (100%) 
No colonies  
in LTC-IC 
0/5 (0%) 0/6 (0%) 
NPM1 mutation A§ 
NPM1 mutation A+ 
(6093 sorted cells) 
~ 45% 
No colonies  
in LTC-IC 
NPM1 WT 
(357 sorted cells) 
0/6 (0%) 
CML 1  t(9;22)(q34;q11) 99/100 (99%) 
#
 5/5 (100%) 97/100 (97%) 3/3 (100%) 
Investigated by: 
#
 fluorescence in situ hybridization; § fragment length analysis; $
AML: acute myeloid leukaemia; CML: chronic myeloid leukaemia; ITD: internal tandem duplication; LTC-IC: long-term colony-
initiating cell assay; NK: normal karyotype; WT: wild type. 
 Sanger sequencing 
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-  
 
  - 
 
 
 
 
Sorted 
cells 
VAF 
(%) 
LTC-IC 
aberration-positive 
colonies (n)/ 
total colonies 
evaluated (N) 
Sorted 
cells 
VAF 
(%) 
LTC-IC 
aberration-positive 
colonies (n)/ 
total colonies 
evaluated (N) 
AML 3  
IDH1 c.394C>T 45  46  
N/A 
30  0/16 (0%)
$
 
ASXL1 c.1934dupG 38  48  44  5/13 (38%)*# 
EZH2 c.1331T>A 42  49  32 % ND 
EZH2 c.394C>A 46  45  20  ND 
RUNX1 c.508 + 2T>C 41  48  19  ND 
RUNX1 
c.1283_1288delins10 
38  47  16 % ND 
JAK2 c.1849G>T 43  45  33  ND 
AML 4  
FLT3-ITD c.1770_1793 
dup 
47  50  
N/A 
9  0/16 (0%)* 
NPM1 
c.860_863dupTCTG 
41  46  23  0/16 (0%)* 
WT1 exon 9 c.1379delT 46  51  6  0/16 (0%)* 
AML 5  
NPM1 
c.860_863dupTCTG 
38  26  
N/A 
0  0/6 (0%)* 
TET2 c.1767delT 47  51  45  6/6 (100%)* 
TET2 c.1932delA 49  46  55 6/6 (100%)* 
ZRSR2 c.827+ 1G>A 98 § 100 § 100 § 6/6 (100%)$ 
Investigated by * fragment length analysis or 
$ 
Sanger sequencing  
# 
three colonies were inconclusive 
§ 
AML: acute myeloid leukaemia; BM: bone marrow; CFC: colony forming cell; ITD: internal tandem duplication; 
LTC-IC: long-term colony-initiating cell assay; N/A: not applicable, ND: not done; NGS: next generation 
sequencing; VAF: variant allele frequency 
male patient with ZRSR2 mutation on chromosome X 
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-
In the left column, gating of the ALDHbr subset on the CD14- cells is 
shown for each patient sample with back-gating of the ALDHbrCLEC12A+ (blue) and 
the ALDHbrCD34+CLEC12A- (red) cell subsets. In the centre column, the distribution 
of the ALDHbrCLEC12A+ and ALDHbrCD34+CLEC12A- cells subsets are shown in a 
CLEC12A vs. CD34 plot. In the right column, back-gating of the ALDHbrCLEC12A+ 
(blue) and the ALDHbr
 
CD34+CLEC12A- (red) cells into CD14- cells displayed in a 
CD38 vs. CD34 plot is shown in order to view the expression of CD38 on the two cell 
subsets.   
- A. CFCs/500 initially 
seeded ALDHbrCLEC12A+ cells. B. CFCs/500 initially seeded 
ALDHbr
AML: acute myeloid leukaemia; BFU-E: burst forming unit-erythroid; CFC: colony-forming 
cell; CFU-E; colony-forming unit erythroid; CFU-GEMM: mixed lineage colony-forming unit; 
CFU-GM: colony-forming unit granulocyte-macrophage; CML: chronic myeloid leukaemia; 
LTC-IC: long-term colony-initiating cell assay; NBM: normal bone marrow; UC: uncountable 
due to over-plating; UI: unidentifiable colony. 
CD34+CLEC12A- cells.  
 
- 
The VAFs of the 7 identified mutations were equally high in the 
ALDHbrCLEC12A+ cell subset, while the VAFs varied in the 
ALDHbr
HSC: haematopoietic stem cell; LSC: leukaemic stem cell; LTC-IC: long-term colony-
initiating cell assay; VAF: variant allele frequency 
CD34+CLEC12A- cell subset, indicating a linear accumulation of mutations in 
the most immature cells. 
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